NatiVita presented an analysis of new scientific data on the optimal use of trastuzumab in breast cancer
The medical department of NatiVita has prepared a scientific review “How to optimize trastuzumab adjuvant treatment of early-stage HER2-positive breast cancer”, which was published in the leading Belarusian professional publication in the field of oncology “Oncological Journal” (Oncological Journal 2020; 14(2-3): 131-140).
The introduction of trastuzumab into clinical practice has significantly improved the treatment outcomes for HER2-positive breast cancer. 12 months treatment course of trastuzumab had become the standard of treatment for the early stages of the disease. However, long-term anticancer therapy is associated with a number of toxic effects (in particular, from the heart) and is costly from a financial point of view. Is it possible to reduce the duration of trastuzumab treatment without losing its effectiveness? – is a relevant question for both clinicians and healthcare organizers.
The authors concluded that there was no convincing evidence of a possibility to make a standardized transition to a shorter trastuzumab course and outlined further ways to improve the effectiveness of HER2-positive breast cancer treatment. They based their conclusion on a review of all completed and published to date scientific publications of randomized clinical trials on the problem. The authors analyzed designs, patient populations, and outcomes (indicators of treatment efficacy and safety) of those trials, as well as presented and discussed the results of meta-analyses of research data and expert opinions on the issue.
The preparation and publication of the review on the optimization of breast cancer targeted therapy in the leading scientific oncological journal of the Republic of Belarus is an important component of NatiVita’s activities as an accredited scientific organization. This is further evidence of the company’s long-term commitment to finding and supporting the implementation of sound and evidence-based decisions in clinical practice.
The authors express their gratitude to the article scientific reviewer, Doctor of Medical Sciences, Professor Nina Nikolaevna Akhmed for critical comments, recommendations, and a high assessment of the work, and thank the editors of the Oncological Journal for fruitful cooperation.
Breast cancer is an important social and medical problem. In 2018, the disease was first diagnosed in more than two million women worldwide and had caused more than 600,000 deaths. In Belarus, about 45 thousand patients with breast cancer are registered with oncologists, every year several thousand new cases are detected, and more than a thousand patients die.
HER2-positive breast cancer is one of the most aggressive types of breast cancer. HER2 (Human Epidermal growth factor Receptor 2) is normally present on the surface of most epithelial cells and regulates cell growth, survival, reproduction, and differentiation. In breast cancer, in some patients, the number of HER2 receptors on the surface of tumor cells scales up massively (overexpression). This leads the tumor cell to receive an enhanced signal to multiply and metastasize. A targeted effect on overexpressed HER2 receptors can stop or slow down the progression of the disease.
Trastuzumab is a monoclonal antibody that specifically binds to HER2 receptors, thereby suppressing their abnormal function.
“Oncological Journal” (https://omr.by/spetsialistam/onkologicheskij-zhurnal) is a peer-reviewed quarterly scientific and practical publication, the printed organ of the “Belarusian Society of Oncologists” public association. The journal publishes problematic and review information, summarizes the best practices of domestic and foreign oncology. It is designed for researchers, graduate students, clinical residents, oncologists, radiation therapists and diagnosticians, chemotherapists, ultrasound and laboratory diagnostics specialists, surgeons, and doctors of other specialties. The editorial board of the journal includes recognized authoritative specialists in various fields of oncology from Belarus, the CIS countries, and the European Union. The full-text version of the journal is available in the scientific electronic library eLIBRARY.RU (https://www.elibrary.ru/defaultx.asp).